4-benzyl-3-crotonyl-2-oxazolidinone has been researched along with didymin in 1 studies
| Studies (4-benzyl-3-crotonyl-2-oxazolidinone) | Trials (4-benzyl-3-crotonyl-2-oxazolidinone) | Recent Studies (post-2010) (4-benzyl-3-crotonyl-2-oxazolidinone) | Studies (didymin) | Trials (didymin) | Recent Studies (post-2010) (didymin) |
|---|---|---|---|---|---|
| 13 | 0 | 9 | 21 | 0 | 20 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Huang, Q; Lin, X; Lu, C; Lu, S; Nie, J; Zhu, X; Zhuo, L | 1 |
1 other study(ies) available for 4-benzyl-3-crotonyl-2-oxazolidinone and didymin
| Article | Year |
|---|---|
Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1; Cytokines; Flavonoids; Glycosides; Humans; Inflammation Mediators; Lipid Peroxidation; Male; Mice; Mice, Inbred ICR; Origanum; Oxazolidinones; Phosphatidylethanolamine Binding Protein; RAW 264.7 Cells; Reactive Oxygen Species | 2017 |